LMR Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

LMR Partners’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,451	Closed	-$72.3K	–	1734
2026 Q1	$72.3K	Sell	3,451 -18,223	-84%	-$410K	﹤0.01%	1280
2025 Q4	$499K	Buy	+21,674	New	+$713K	﹤0.01%	1124
2024 Q3	–	Sell	-145,000	Closed	-$7.39M	–	1473
2024 Q2	$5.96M	Buy	+145,000	New	+$6.19M	0.05%	290
2021 Q3	–	Sell	-12,064	Closed	-$1.15M	–	1158
2021 Q2	$1.15M	Buy	+12,064	New	+$1.26M	0.02%	496

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

LMR Partners's RARE Position: Q2 2026 in Review

LMR Partners sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2026, closing a stake of 3,451 shares — an estimated $72.3K sold.

LMR Partners first reported a position in RARE in Q2 2021 and held it in 4 quarters. The position peaked at $5.96M in Q2 2024. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

LMR Partners reported no remaining Ultragenyx Pharmaceutical position as of Q2 2026 after selling out during the quarter.
LMR Partners sold 3,451 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $72.3K.
LMR Partners first reported a position in Ultragenyx Pharmaceutical in Q2 2021 and held it in 4 quarters.
LMR Partners's Ultragenyx Pharmaceutical position peaked at $5.96M in Q2 2024.
311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.